Vaxart, Inc. (VXRT)
0.4344
0.00 (0.00%)
USD |
OTCM |
Oct 09, 16:00
Vaxart Price to Book Value : 1.281 for Oct. 9, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 1.281 |
| October 08, 2026 | 1.281 |
| October 07, 2026 | 1.274 |
| October 06, 2026 | 1.286 |
| October 05, 2026 | 1.238 |
| October 02, 2026 | 1.288 |
| October 01, 2026 | 1.297 |
| September 30, 2026 | 1.327 |
| September 29, 2026 | 1.327 |
| September 28, 2026 | 1.350 |
| September 25, 2026 | 1.341 |
| September 24, 2026 | 1.332 |
| September 23, 2026 | 1.414 |
| September 22, 2026 | 1.428 |
| September 21, 2026 | 1.450 |
| September 18, 2026 | 1.433 |
| September 17, 2026 | 1.474 |
| September 16, 2026 | 1.397 |
| September 15, 2026 | 1.415 |
| September 14, 2026 | 1.444 |
| September 11, 2026 | 1.430 |
| September 10, 2026 | 1.436 |
| September 09, 2026 | 1.440 |
| September 08, 2026 | 1.485 |
| September 04, 2026 | 1.459 |
| Date | Value |
|---|---|
| September 03, 2026 | 1.452 |
| September 02, 2026 | 1.446 |
| September 01, 2026 | 1.453 |
| August 31, 2026 | 1.504 |
| August 28, 2026 | 1.479 |
| August 27, 2026 | 1.484 |
| August 26, 2026 | 1.487 |
| August 25, 2026 | 1.481 |
| August 24, 2026 | 1.476 |
| August 21, 2026 | 1.518 |
| August 20, 2026 | 1.532 |
| August 19, 2026 | 1.467 |
| August 18, 2026 | 1.460 |
| August 17, 2026 | 1.456 |
| August 14, 2026 | 1.602 |
| August 13, 2026 | 1.651 |
| August 12, 2026 | 1.650 |
| August 11, 2026 | 1.643 |
| August 10, 2026 | 1.695 |
| August 07, 2026 | 1.623 |
| August 06, 2026 | 1.680 |
| August 05, 2026 | 1.738 |
| August 04, 2026 | 1.769 |
| August 03, 2026 | 1.740 |
| July 31, 2026 | 1.592 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Agenus, Inc. | -- |
| Amgen, Inc. | 19.19 |
| Anika Therapeutics, Inc. | 1.909 |
| BioCryst Pharmaceuticals, Inc. | -- |
| Imunon, Inc. | 1.203 |
Price to Book Value Related Metrics
| PE Ratio | 2.732 |
| PS Ratio | 0.4261 |
| Price to Free Cash Flow | 3.103 |
| Price | 0.4344 |
| Earnings Yield | 36.60% |
| Market Cap | 105.49M |
| Operating PE Ratio | 2.615 |
| Normalized PE Ratio | 2.732 |